Skip to content
Drug Regulatory Authority of Pakistan

Drug Regulatory Authority of Pakistan

Ministry of National Health Services, Regulations & Coordination

اردو |  English
  • facebook
  • twitter
  • envelope

Menu

  • About Us
    • DRAP at a Glance
    • Organization
    • Legislation
    • Boards and Committees
    • Quality Management System
    • Contact Us
  • Therapeutic Goods
    • Drugs
    • Medical Devices
    • Alternative Medicine
    • Controlled Substances
    • Emergency Use Authorizations
    • Clinical Trials Oversight
    • Licensing and Inspections
    • Quality Controls Labs
    • Import & Export
    • Advertisement Approvals
  • Safety Info
    • Product Recalls
    • Safety Communication
    • Safety Reporting
    • Report a Problem
  • News & Updates
    • Regulatory Updates
    • Press Releases
    • Careers
    • Tenders
    • Events
  • Publications
    • Guidelines
    • Newsletters
    • Regulatory Procedures
    • Regulatory Fees
    • Application Forms
    • Public Consultation
    • Minutes of the Meetings
  • E-Services
    • MIS Systems
    • Online Verification Services
  • Covid-19
    • News & Updates
    • COVID-19 Drugs Availability
Home > News & Updates > Regulatory Updates > Drugs > DRAP issued guidance on Remote Virtual Inspection (RVI) for GMP Assessment of overseas manufacturing facilities for registration of finished Pharmaceutical Drugs and Biologicals

DRAP issued guidance on Remote Virtual Inspection (RVI) for GMP Assessment of overseas manufacturing facilities for registration of finished Pharmaceutical Drugs and Biologicals

Ijaz Mustafa Drugs, General September 27, 2022September 28, 2022

Virtual_Inspection_LetterDownload
  • ← Minutes of 320th Meeting of Registration Board held on 29th -31st August, 2022
  • National Task Force (NTF) for Eradication of Spurious and Unregistered Therapeutic goods; CEO DRAP Chaired the meeting of NTF Core Team →
  • Drugs
  • Medical Devices
  • Alternative Medicines
  • Controlled Substances
  • Licensing and Inspections
  • Clinical Trials
  • Pharmacovigilance
  • Advertisements
  • General

Quick Navigation

Archives

Drug Regulatory Authority of Pakistan

  • Islamabad | Karachi | Lahore | Peshawar | Quetta
  • Phone: 0800-03727 (Mon to Fri 08:00AM to 04:00PM)
  • Website: www.dra.gov.pk
Developed by MIS Division. All rights reserved to Drug Regulatory Authority of Pakistan
  • Contact Us
  • Report a Problem